Achieving and Maintaining Compliance Using Continuous Monitoring Systems

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-15-2014
Volume 2014 eBook
Issue 2

Challenges encountered when implementing a continuous monitoring system are reviewed.

 

There are a number of challenges when implementing a continuous monitoring system.

The author presents issues encountered at Novo Nordisk and discusses how expanding the scope of monitoring, together with frequent and thorough review of data, can help keep a facility in compliance.

Download

Pharmaceutical Technology’s 2014 Bioprocessing and Sterile Manufacturing eBook

.

 

Articles in this issue
Continious-Biopharma185.jpg
Potential Benefits Drive Interest in Continuous Manufacturing
stephaniedubois200.jpg
Continuous Bioprocessing Challenges
PTebook0514_Cross-Contamination185.jpg
Determining Cross-Contamination Risks in Multiproduct Biopharmaceutical Facilities
PTebook0514_Continuous-Monitoring_1851431659146699.jpg
Achieving and Maintaining Compliance Using Continuous Monitoring Systems
PTebook0514_Telstar185.jpg
Optimizing the Sterilization of Liquids in Sealed Containers
par-almhelm200.jpg
Using Modular Systems in Biopharmaceutical Manufacturing
PTebook_Genzyme185.jpg
Determining Protein Oxidation Induced During Fill-Finish Operations
PTebook0514_SingleUse_185.jpg
Single-Use Technology in Parenteral Fill/Finish
Recent Videos
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Behind the Headlines episode 6
Behind the Headlines episode 5
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Orexo and Abera Partner to Develop Nasal Powder Vaccines

Feliza Mirasol
December 20th 2024
Article

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Novo Nordisk to Establish New Production Facility for Rare Disease Therapies in Denmark with DKK 8.5 Billion Investment

Feliza Mirasol
December 17th 2024
Article

Novo Nordisk will use the DKK 8.5 billion (US$1.2 billion) to build a new modular and flexible production facility in Odense, Denmark, that will produce multiple products for rare diseases.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Novo Nordisk Gains Manufacturing Sites from Novo Holdings and Novavax while EC Approves Catalent Acquisition

Feliza Mirasol
December 11th 2024
Article

The European Commission has approved Novo Holdings' acquisition of Catalent, which includes the related sale of three manufacturing sites to Novo Nordisk, which is also acquiring the Czech Republic manufacturing site of Novavax for $200 million.

3D printed pills and drugs, future of medicine. 3D Printing Drugs In Pharmacies. Multi-colored, various drugs, pills, capsules. Pharmaceutical medical concept | Image Credit: © irissca - © irissca - stock.adobe.com

Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications

Gary Ritchie;Sharon Flank
December 10th 2024
Article

This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.